[HTML][HTML] Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or …
Background Approximately 30%–45% of patients with nondialysis CKD have iron deficiency.
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
[PDF][PDF] Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or …
M Guedes, DG Muenz, J Zee, B Bieber, B Stengel… - 2021 - academia.edu
ABSTRACT Background Approximately 30%–45% of patients with nondialysis CKD have
iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In …
iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In …
Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without …
M Guedes, DG Muenz, J Zee, B Bieber, B Stengel… - 2021 - cabidigitallibrary.org
Abstract Background: Approximately 30%-45% of patients with nondialysis CKD have iron
deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In …
deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In …
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without …
M Guedes, DG Muenz, J Zee, B Bieber… - Journal of the …, 2021 - europepmc.org
Background Approximately 30%-45% of patients with nondialysis CKD have iron deficiency.
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without …
M Guedes, DG Muenz, J Zee… - Journal of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Approximately 30%-45% of patients with nondialysis CKD have iron deficiency.
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
[HTML][HTML] Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or …
M Guedes, DG Muenz, J Zee, B Bieber… - Journal of the …, 2021 - ncbi.nlm.nih.gov
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality
and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia - PMC Back …
and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia - PMC Back …
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without …
M Guedes, DG Muenz, J Zee, B Bieber… - Journal of the American …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background</jats: title>< jats: p content-type=" flushleft">
Approximately 30%–45% of patients with nondialysis CKD have iron deficiency. Iron therapy …
Approximately 30%–45% of patients with nondialysis CKD have iron deficiency. Iron therapy …
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without …
M Guedes, DG Muenz, J Zee, B Bieber… - Journal of the …, 2021 - europepmc.org
Background Approximately 30%-45% of patients with nondialysis CKD have iron deficiency.
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …
Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or …